File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Prevention of herpes zoster in acquired immunocompromised conditions: Review of updates and perspectives from Hong Kong

TitlePrevention of herpes zoster in acquired immunocompromised conditions: Review of updates and perspectives from Hong Kong
Authors
Keywordsguidelines
herpes zoster
Hong Kong
immunocompromised
vaccination
Varicella-zoster virus
Issue Date1-Jan-2025
PublisherTaylor and Francis Group
Citation
Human Vaccines & Immunotherapeutics, 2025, v. 21, n. 1 How to Cite?
AbstractPatients with acquired immunocompromising conditions face considerable risk of developing herpes zoster (HZ). Based on the underlying medical conditions and degree of immune dysfunction, these patients require tailored strategies for HZ prevention. In Hong Kong, there is currently a lack of guidelines addressing the unique needs of this vulnerable population, including the use of prophylactic measures such as antivirals and vaccines. An expert panel comprising clinical immunologists, nephrologists, infectious diseases specialists, rheumatologists, hematologists and oncologists in Hong Kong met to review current literature and international guidelines to propose a locally adapted decision-making framework for HZ prophylaxis, in patients with acquired immunocompromised conditions. This article summarizes the consensus and presents a guiding criteria for clinicians to navigate the complexities associated with HZ prevention, in the context of acquired immunodeficiency.
Persistent Identifierhttp://hdl.handle.net/10722/357714
ISSN
2023 Impact Factor: 4.1
2023 SCImago Journal Rankings: 0.927
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorYap, Desmond Y.H.-
dc.contributor.authorChan, Gordon C.K.-
dc.contributor.authorHo, So-
dc.contributor.authorWong, Raymond S.M.-
dc.contributor.authorChan, Stephen L.-
dc.contributor.authorLee, Victor H.F.-
dc.contributor.authorLam, Wilson-
dc.contributor.authorLi, Philip H.-
dc.date.accessioned2025-07-22T03:14:28Z-
dc.date.available2025-07-22T03:14:28Z-
dc.date.issued2025-01-01-
dc.identifier.citationHuman Vaccines & Immunotherapeutics, 2025, v. 21, n. 1-
dc.identifier.issn2164-5515-
dc.identifier.urihttp://hdl.handle.net/10722/357714-
dc.description.abstractPatients with acquired immunocompromising conditions face considerable risk of developing herpes zoster (HZ). Based on the underlying medical conditions and degree of immune dysfunction, these patients require tailored strategies for HZ prevention. In Hong Kong, there is currently a lack of guidelines addressing the unique needs of this vulnerable population, including the use of prophylactic measures such as antivirals and vaccines. An expert panel comprising clinical immunologists, nephrologists, infectious diseases specialists, rheumatologists, hematologists and oncologists in Hong Kong met to review current literature and international guidelines to propose a locally adapted decision-making framework for HZ prophylaxis, in patients with acquired immunocompromised conditions. This article summarizes the consensus and presents a guiding criteria for clinicians to navigate the complexities associated with HZ prevention, in the context of acquired immunodeficiency.-
dc.languageeng-
dc.publisherTaylor and Francis Group-
dc.relation.ispartofHuman Vaccines & Immunotherapeutics-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectguidelines-
dc.subjectherpes zoster-
dc.subjectHong Kong-
dc.subjectimmunocompromised-
dc.subjectvaccination-
dc.subjectVaricella-zoster virus-
dc.titlePrevention of herpes zoster in acquired immunocompromised conditions: Review of updates and perspectives from Hong Kong -
dc.typeArticle-
dc.identifier.doi10.1080/21645515.2025.2463185-
dc.identifier.pmid40063340-
dc.identifier.scopuseid_2-s2.0-105000087111-
dc.identifier.volume21-
dc.identifier.issue1-
dc.identifier.eissn2164-554X-
dc.identifier.isiWOS:001440842700001-
dc.identifier.issnl2164-5515-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats